Italy's MoH requests Insmed's Iplex for ALS treatment
Insmed of the USA has been requested by the Italian Ministry of Health, to make its drug, Iplex (rhIGFI/rhIGFBP-3), available to physicians in Italy to treat patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.
The request comes as a result of several Italian Court rulings ordering the Italian National Health System to provide the drug to specific ALS patients who have petitioned the Court. Through an agreement with Cephalon, which holds European patent rights to IGF-1 in the treatment of ALS, Insmed will be able to provide Iplex to physicians in Italy. It will be distributed through an expanded access program, with Insmed receiving payment for the drug from the Italian health authorities.
In Italy, there are an estimated 1,000 new cases of ALS each year and the Ministry has tried for several years to provide IGF, which is approved in the USA, for these patients and, in doing so, has contacted several drugmakers worldwide, according to Insmed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze